Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025

Rhea-AI Summary

Cidara Therapeutics (Nasdaq: CDTX) will present late-breaking Phase 2 clinical data for its antiviral influenza candidate CD388 at ID Week 2025 in Atlanta on October 20, 2025. The randomized, placebo-controlled trial evaluates safety and efficacy of CD388 for prevention of illness due to Influenza A and B in healthy unvaccinated participants.

Presentation: "A Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of CD388, a Novel Drug-Fc-Conjugate, for Prevention of Illness due to Influenza A and B in Healthy Unvaccinated Participants." Presenter: James Alexander MD, MPH, FIDSA. Session: Extra, Extra! New Info on Treating and Preventing RSV and Influenza. Location B401-B402, Monday, October 20, 2025, 3:15 PM - 4:30 PM ET.

SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak^® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will be presenting late-breaking Phase 2 clinical data on its antiviral influenza candidate, CD388, during ID Week 2025, taking place October 19-22, 2025, in Atlanta, GA.

Presentation details are summarized below:

Presentation Title: A Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of CD388, a Novel Drug-Fc-Conjugate, for Prevention of Illness due to Influenza A and B in Healthy Unvaccinated Participants
Presenter: James Alexander MD, MPH, FIDSA
Session: Extra, Extra! New Info on Treating and Preventing RSV and Influenza
Session Location: B401-B402
Session Date and Time: Monday, October 20, 2025, 3:15 PM - 4:30 PM ET

About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak^® platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025 and initiated its Phase 3 ANCHOR trial in September 2025. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
(628) 234-3889
mfitzhugh@lifescicomms.com

FAQ

When will Cidara Therapeutics (CDTX) present CD388 Phase 2 data at ID Week 2025?

Cidara will present on October 20, 2025 from 3:15 PM to 4:30 PM ET in session B401-B402.

What is the focus of the CD388 late-breaking Phase 2 presentation for CDTX?

The presentation reports a randomized, placebo-controlled trial evaluating safety and efficacy of CD388 to prevent illness from Influenza A and B in healthy unvaccinated participants.

Who is presenting the CD388 data for Cidara (CDTX) at ID Week 2025?

The data will be presented by James Alexander MD, MPH, FIDSA during the RSV and Influenza session.

Where and in which session will CDTX present CD388 results at ID Week 2025?

The presentation is in Atlanta, GA at ID Week 2025 in the session titled Extra, Extra! New Info on Treating and Preventing RSV and Influenza, location B401-B402.

What trial design is reported for CDTX's CD388 Phase 2 study?

The study is described as a randomized, placebo-controlled trial assessing prevention of influenza illness in healthy unvaccinated participants.